[
1. Handforth C, D’Oronzo S, Coleman R, Brown J. Cancer Treatment and Bone Health. Calcif Tissue Int. 2018; 102:251.10.1007/s00223-017-0369-x580579629353450
]Search in Google Scholar
[
2. Coleman R, Hadji P, Body JJ et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020; 31:1650.10.1016/j.annonc.2020.07.01932801018
]Search in Google Scholar
[
3. Shapiro CL, Van Poznak C, Lacchetti C et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019; 37:2916.10.1200/JCO.19.0169631532726
]Search in Google Scholar
[
4. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006; 24:675.10.1200/JCO.2005.02.351516446340
]Search in Google Scholar
[
5. Sverrisdóttir A, Fornander T, Jacobsson H et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004; 22:3694.10.1200/JCO.2004.08.14815365065
]Search in Google Scholar
[
6. Gralow JR, Biermann JS, Farooki A et al. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw. 2013; 11 Suppl 3:S1.10.6004/jnccn.2013.021523997241
]Search in Google Scholar
[
7. Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011; 47:683.10.1016/j.ejca.2010.11.024421159421324674
]Search in Google Scholar
[
8. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9:840.10.1016/S1470-2045(08)70204-318718815
]Search in Google Scholar
[
9. Van Poznak C, Morris P, D’Andrea G et al. Bone Mineral Density (BMD) Changes at 1 Year in Postmenopausal Women Who Are Not Receiving Adjuvant Endocrine Therapy for Breast Cancer (BCA). Cancer Res. 2009; 69S: SABCS #1066.10.1158/0008-5472.SABCS-09-1066
]Search in Google Scholar
[
10. Love RR, Mazess RB, Barden HS et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992; 326:852.10.1056/NEJM1992032632613021542321
]Search in Google Scholar
[
11. Gnant M, Pfeiler G, Steger GG et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20:339.10.1016/S1470-2045(18)30862-330795951
]Search in Google Scholar
[
12. Coleman R, Hadji P. Denosumab and fracture risk in women with breast cancer. Lancet. 2015; 386:409.10.1016/S0140-6736(15)61032-726040500
]Search in Google Scholar
[
13. Tsourdi E, Zillikens MC, Meier C et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020.10.1210/clinem/dgaa75633103722
]Search in Google Scholar
[
14. Coleman R, Powles T et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015; 386:1353.10.1016/S0140-6736(15)60908-426211824
]Search in Google Scholar
[
15. O’Carrigan B, Wong MH, Willson ML et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017; 10:CD003474.10.1002/14651858.CD003474.pub4648588629082518
]Search in Google Scholar
[
16. Mauri D, Valachis A, Polyzos NP et al. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. J Natl Compr Canc Netw. 2010; 8:279.10.6004/jnccn.2010.002020202461
]Search in Google Scholar
[
17. Valachis A, Polyzos NP, Coleman RE et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013; 18:353.10.1634/theoncologist.2012-0261363952023404816
]Search in Google Scholar
[
18. Coleman R, Finkelstein DM, Barrios C et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020; 21:60.10.1016/S1470-2045(19)30687-431806543
]Search in Google Scholar
